Dexanabinol in Patients With Brain Cancer

Inclusion Criteria: * Histologically or radiologically confirmed diagnosis of brain cancer: * glioblastoma (GBM), * anaplastic astrocytoma (AA), * anaplastic oligodendroglioma (AO), * anaplastic mixed oligoastrocytoma (AMO), * low grade gliomas, * brain metastases, * meningiomas, or * leptomeningeal metastases * Has failed prior standard therapy including maximal safe surgical resection, radiation therapy (when appropriate for the specific cancer type), and systemic therapy. * For diagnosis of GBM: has undergone at least one prior surgical gross-total or subtotal tumor resection, a course of postoperative radiation therapy with concurrent temozolomide, and at least 2 cycles of maintenance temozolomide. * For diagnosis of meningioma: has no other option of standard therapy such as surgical resection (partial or total resection) or radiation. * Has progression of brain cancer and measurable disease by magnetic resonance imaging (MRI) or computed tomography (CT) scan. * Age ≥ 18 years. * Karnofsky Performance Status ≥ 60%. (Appendix A). Subjects must have a life expectancy of equal to or greater than 8 weeks. * Organ and Marrow Function Requirements Hematology: * Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L * Platelet count ≥ 100 x 109/L * Hemoglobin ≥ 9.0 g/dL * White blood cell (WBC) count ≥ 3.0 x 109/L Biochemistry: * AST/SGOT and ALT/SGPT ≤ 2.5 x institution's ULN * Total bilirubin ≤ 1.5 x institution's ULN * Serum creatinine ≤ 1.5 x institution's ULN or 24-hour creatinine clearance ≥ 50 ml/min * Alkaline phosphatase (ALP) ≤ 2.5 x ULN unless considered tumor related * Estimated GFR \> 50 ml/min (based on Wright formula) Coagulation: * INR \< 1.5 x institution's ULN * PT/aPTT within institution's normal range, unless receiving therapeutic low molecular weight heparin * Contraception Woman of child-bearing potential and man with partners of child-bearing potential agrees to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 30 days following completion of therapy. * Woman of child-bearing potential has negative pregnancy test before the initiation of study drug dosing. Exclusion Criteria: * Current or anticipated use of other investigational agents. * Current or anticipated use of enzyme-inducing anti-epileptic drugs (EIAED). * Insufficient time for recovery from prior therapy: * less than 28 days from any investigational agent, * less than 28 days from prior cytotoxic therapy (except 23 days from prior temozolomide, 14 days from vincristine, 42 days from nitrosoureas, 21 days from procarbazine administration), and * less than 7 days for non-cytotoxic agents, e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, etc. (radiosensitizer does not count). * Less than 4 weeks from surgery or insufficient recovery from surgical-related trauma or wound healing. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to dexanabinol. * History of allergic reactions to medicines containing polyoxyethylated castor oil that are not controlled with premedications. * Severe or uncontrolled medical disorder that would, in the investigator's opinion, impair ability to receive study treatment (i.e., uncontrolled diabetes, chronic renal disease, chronic pulmonary disease or active, uncontrolled infection). * Electrolyte abnormality that cannot be corrected to normal levels prior to initiating study drug. * Known diagnosis of human immunodeficiency virus (HIV) infection. * Impaired cardiac function including any of the following: * Congenital long QT syndrome or a known family history of long QT syndrome; * History or presence of clinically significant ventricular or atrial tachyarrhythmias * Clinically significant resting bradycardia (\< 50 beats per minute) * Inability to monitor the QT interval by ECG * QTc \> 450 msec on baseline ECG. If QTc \> 450 and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc * Myocardial infarction within 1 year of starting study drug * Other clinically significant heart disease (e.g., unstable angina, congestive heart failure, or uncontrolled hypertension) * Pregnant or nursing. There is a potential for congenital abnormalities and for this regimen to harm nursing infants.